NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00142454
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : September 21, 2007
American Society of Clinical Oncology
Information provided by:
Ludwig Institute for Cancer Research

Brief Summary:

This study evaluates a cancer vaccine in melanoma patients who have resected melanoma but are at high risk for recurrence (stages IIB-III). This is a single arm, open label, pilot/phase I study evaluating safety and immunogenicity of NY-ESO-1 protein vaccination with Imiquimod as an adjuvant.

Imiquimod is a FDA approved immune response modifier for the treatment of HPV associated genital warts (but used for a different indication here) and has been shown to attract and mature dendritic cells in areas of topical application. This will be utilized in this application to inject a protein vaccine into this site, to prime and boost anti-NY-ESO-1 immune responses.

9 patients will be treated to receive 4 vaccination cycles, 21 days apart. Each vaccination cycle consists of topical application of Imiquimod 250mg to healthy skin of extremities for the first five days of each cycle and intradermal injection of NY-ESO-1 protein 100mcg to the pretreated area on day 3.

Immunization will be assessed by T-cell assays, NY-ESO-1 specific antibody titers, and evaluation of 3 small skin biopsies.

Condition or disease Intervention/treatment Phase
Malignant Melanoma Biological: NY-ESO-1 protein Drug: Imiquimod Phase 1

Study Type : Interventional  (Clinical Trial)
Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: NY-ESO-1 Protein Vaccination in Malignant Melanoma Administered With Imiquimod as Adjuvant
Study Start Date : August 2005
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
Drug Information available for: Imiquimod

Primary Outcome Measures :
  1. Safety

Secondary Outcome Measures :
  1. Immunogenicity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed, resected AJCC Stage IIB, IIC or III malignant melanoma
  • Fully recovered from surgery
  • Age >18 years.
  • ECOG performance status <2
  • Adequate organ and marrow function.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Chemotherapy, immunotherapy (including interferon), or radiotherapy within 4 weeks prior to first dosing of study agent.
  • Prior treatment with NY-ESO-1 vaccines.
  • Known HIV infection or autoimmune disease (RA, SLE). Patients with vitiligo or melanoma-associated hypopigmentation are not excluded.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to imiquimod or other agents used in the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnancy or lactation.
  • Women of childbearing potential not using a medically acceptable means of contraception.
  • Patients with known history of inflammatory skin disorders, as imiquimod might exacerbate these conditions.
  • Patients who receive chronic corticosteroid or immunosuppressive therapies.
  • Lack of availability for immunological and clinical follow-up assessments.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00142454

United States, New York
NYU Cancer Institute
New York City, New York, United States, 10016
Sponsors and Collaborators
Ludwig Institute for Cancer Research
American Society of Clinical Oncology
Principal Investigator: Nina Bhardwaj, MD, PhD New York University School of Medicine
Study Director: Sylvia Adams, MD New York University School of Medicine Identifier: NCT00142454     History of Changes
Other Study ID Numbers: NYU 04-53, LUD2004-006
First Posted: September 2, 2005    Key Record Dates
Last Update Posted: September 21, 2007
Last Verified: September 2007

Keywords provided by Ludwig Institute for Cancer Research:
Malignant melanoma
Stages IIB-III

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Interferon Inducers